Depo-Provera Lawsuits

Investigating Claims Involving Depo-Provera and Meningioma Brain Tumors

Grewal Law PLLC is investigating potential claims involving Depo-Provera, Depo-SubQ Provera 104, and other medroxyprogesterone acetate injections after studies, regulatory action, and growing litigation linked these drugs to meningiomas, a type of tumor that forms in the tissue surrounding the brain and spinal cord.

If you or your loved one were diagnosed with a meningioma after receiving Depo-Provera shots, you may be entitled to compensation. Our attorneys can review the facts and discuss whether you may have grounds to pursue a claim.

Call (888) 211-5798 or contact us online for a FREE consultation. We’re available 24/7 and work on contingency, which means no upfront cost and no fee unless we win.

Proven Counsel for High-Stakes Pharmaceutical Litigation

Grewal Law PLLC has the experience and resources to handle complex claims against major drug manufacturers. We represent people and families in mass tort and serious injury cases and know what it takes to pursue powerful defendants in medically demanding litigation.

• Over $1 billion recovered for clients 
• Award-winning attorneys with 100+ years of combined experience 
• Proven results against major corporations, insurers, and institutions 
• Thousands of clients served 
• No fee unless we recover compensation

Learn more about us and our client victories.

Serious Brain Tumor Risks Linked to Depo-Provera

Depo-Provera lawsuits focus on reports that medroxyprogesterone acetate, the active ingredient in Depo-Provera and Depo-SubQ Provera 104, may increase the risk of meningioma after repeated use, especially long-term use. Meningiomas are often non-cancerous, but they can still be serious. Depending on their size and location, they may press on the brain, affect vision or cognition, cause seizures or chronic headaches, and require surgery, radiation, or long-term monitoring.

This issue has drawn attention from regulators, researchers, and courts. For example:

• A 2024 BMJ study found that women using Depo-Provera for over a year were 5.6x more likely to develop a brain tumor, especially meningiomas, than those who hadn’t used the drug.
• The European Medicines Agency said in September 2024 that available data showed increased meningioma risk with high-dose medroxyprogesterone acetate used for several years, including injectable products. 
• Pfizer’s labeling now warns about meningioma and instructs that Depo-Provera CI should be discontinued if meningioma is diagnosed

Federal Depo-Provera lawsuits have been centralized in an MDL in the Northern District of Florida. In an MDL, similar federal lawsuits are coordinated before one court for pretrial proceedings, but each plaintiff keeps an individual case and the right to seek compensation based on her own injuries.

Women who developed meningiomas after Depo-Provera use have reported injuries and complications such as:

• Severe or persistent headaches 
• Vision changes or vision loss 
• Seizures 
• Memory problems or cognitive changes 
• Weakness, balance problems, or other neurological symptoms 
• Brain surgery, radiation, or other invasive treatment 
• Lasting neurological impairment